Latest Fund Strategy News

Elixir Energy has locked in a $10 million debt facility secured against its FY26 R&D tax refund to fund the Lorelle-3 appraisal well activities in Queensland’s Taroom Trough. This financial move aims to bolster working capital during a busy operational period.

Deal headlines and big drill hits shared the stage with a brutal sell-off in a handful of tiny raisings. The week’s biggest winners were backed by clear news; the biggest losers showed what happens when buyers vanish after a halt.

Big gains hit wealth platforms while Zip swung the other way as early optimism didn’t stick. Dividends and buy-backs kept coming, but investors still punished stocks where the next step looks unclear.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Talga Group’s application for a major Swedish government grant was declined due to budget constraints, yet the company remains on track with alternative financing to scale its graphite anode production.

Caravel Minerals has secured non-binding Letters of Interest from Finnish and German export credit agencies, marking a significant step in financing its Caravel Copper Project. This European backing complements a diversified funding strategy as the company moves towards a Final Investment Decision.

Austral Resources Australia has voluntarily suspended its shares on the ASX to complete a significant placement and secure a strategic investor commitment, with strong demand reported.

Empire Resources has successfully raised nearly $2.9 million through the first tranche of its planned $5 million placement, with a second tranche pending shareholder approval in March.

Stavely Minerals has locked in a $500,000 unsecured director loan facility to fund its 2026 Scoping Study targeting copper, gold, and silver production. This non-dilutive funding move underscores confidence from within the board as the company advances key projects.

Nexalis Therapeutics has completed a key capital raising milestone, issuing new shares, options, and performance rights following shareholder approval. This move supports the company’s clinical-stage drug development programs targeting pain and mental health.

Kali Metals Limited has successfully raised approximately A$7 million through a Tranche 1 Placement, issuing over 38 million new shares at 18 cents each. This capital injection marks a significant step in the company’s funding strategy.

Judo Capital Holdings Limited has reported a robust half-year result, with profit before tax rising 26% over the prior half and 53% year-on-year, driven by strong SME loan book growth and stable net interest margins.